Key result
Commercially insured US patients meeting THEMIS trial criteria experienced a high rate of death, MI, or stroke (6.21 per 100 person-years) and incurred annualized healthcare costs of US$16,044.
Why the study?
To complement the THEMIS trial by assessing clinical outcomes and healthcare costs in commercially insured US patients similar to those enrolled in THEMIS.
Cohort (n=126,938)
Answers are grounded in this paper and cite their sources.
Patients with T2D and stable CAD without prior MI/stroke experience high rates of cardiovascular events and incur substantial healthcare costs, underscoring the need for effective preventive therapies.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Wittbrodt et al. (2021) conducted a cohort in Type 2 diabetes and stable coronary artery disease (n=126,938). THEMIS-like patient profile (T2D, stable CAD, no prior MI/stroke) vs. T2D-CAD cohort was evaluated on Composite of death, MI, and stroke. Commercially insured US patients meeting THEMIS trial criteria experienced a high rate of death, MI, or stroke (6.21 per 100 person-years) and incurred annualized healthcare costs of US$16,044.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: